{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T08:44:09Z","timestamp":1772095449084,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,2,29]],"date-time":"2016-02-29T00:00:00Z","timestamp":1456704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003579","name":"University of Toronto (CA)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care (CA)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s40258-016-0229-2","type":"journal-article","created":{"date-parts":[[2016,2,29]],"date-time":"2016-02-29T05:28:27Z","timestamp":1456723707000},"page":"313-322","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Using Phase-Based Costing of Real-World Data to Inform Decision\u2013Analytic Models for Atrial Fibrillation"],"prefix":"10.1007","volume":"14","author":[{"given":"Amy","family":"Tawfik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter P.","family":"Wodchis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petros","family":"Pechlivanoglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Hoch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4416-6876","authenticated-orcid":false,"given":"Don","family":"Husereau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray","family":"Krahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,29]]},"reference":[{"issue":"8","key":"229_CR1","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","volume":"129","author":"SS Chugh","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837\u201347.","journal-title":"Circulation"},{"issue":"2","key":"229_CR2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jval.2011.09.009","volume":"15","author":"WP Wodchis","year":"2012","unstructured":"Wodchis WP, Bhatia RS, Leblanc K, Meshkat N, Morra D. A review of the cost of atrial fibrillation. Value Health. 2012;15(2):240\u20138.","journal-title":"Value Health."},{"issue":"3","key":"229_CR3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIR.0b013e318224b037","volume":"124","author":"N Estes","year":"2011","unstructured":"Estes N, Sacco RL, Al-Khatib SM, et al. American Heart Association atrial fibrillation research summit: a conference report from the American Heart Association. Circulation. 2011;124(3):363\u201372.","journal-title":"Circulation"},{"issue":"3","key":"229_CR4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/hrt.2003.014720","volume":"90","author":"JS Steinberg","year":"2004","unstructured":"Steinberg JS. Atrial fibrillation: an emerging epidemic? Heart. 2004;90(3):239\u201340.","journal-title":"Heart"},{"issue":"2","key":"229_CR5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cjca.2012.03.023","volume":"29","author":"DJ O\u2019Reilly","year":"2013","unstructured":"O\u2019Reilly DJ, Hopkins RB, Healey JS, et al. The burden of atrial fibrillation on the hospital sector in Canada. Can J Cardiol. 2013;29(2):229\u201335.","journal-title":"Can J Cardiol"},{"issue":"5","key":"229_CR6","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1524-4733.2006.00124.x","volume":"9","author":"KS Coyne","year":"2006","unstructured":"Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006;9(5):348\u201356.","journal-title":"Value Health."},{"issue":"3","key":"229_CR7","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/hrt.2002.008748","volume":"90","author":"S Stewart","year":"2004","unstructured":"Stewart S, Murphy NF, Murphy N, Walker A, McGuire A, McMurray JJV. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart. 2004;90(3):286\u201392.","journal-title":"Heart"},{"issue":"6","key":"229_CR8","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1161\/STROKEAHA.111.000402","volume":"44","author":"AR Harrington","year":"2013","unstructured":"Harrington AR, Armstrong EP, Nolan PE, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke. 2013;44(6):1676\u201381.","journal-title":"Stroke"},{"issue":"4","key":"229_CR9","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jval.2013.01.009","volume":"16","author":"D Coyle","year":"2013","unstructured":"Coyle D, Coyle K, Cameron C, et al. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health. 2013;16(4):498\u2013506.","journal-title":"Value Health."},{"issue":"2","key":"229_CR10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clinthera.2013.12.011","volume":"36","author":"GYH Lip","year":"2014","unstructured":"Lip GYH, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Clin Ther. 2014;36(2):192\u2013210.","journal-title":"Clin Ther"},{"issue":"2","key":"229_CR11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11239-014-1104-3","volume":"39","author":"C Rognoni","year":"2015","unstructured":"Rognoni C, Marchetti M, Quagliani S, Liberato N. Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. J Thromb Thrombolysis. 2015;39(2):149\u201354.","journal-title":"J Thromb Thrombolysis"},{"key":"229_CR12","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1161\/CIRCOUTCOMES.112.965251","volume":"5","author":"S Lee","year":"2012","unstructured":"Lee S, Anglade MW, Meng J, Hagstrom K, Kluger J, Coleman CI. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. Circ Cardiovasc Qual Outcomes. 2012;5:472\u20139.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"22","key":"229_CR13","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1161\/CIRCULATIONAHA.110.985655","volume":"123","author":"SV Shah","year":"2011","unstructured":"Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123(22):2562\u201370.","journal-title":"Circulation"},{"issue":"5","key":"229_CR14","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1160\/TH11-02-0089","volume":"105","author":"SV Sorensen","year":"2011","unstructured":"Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J, Bradley-Kennedy C, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost. 2011;105(5):908\u201319.","journal-title":"Thromb Haemost"},{"key":"229_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-154-1-201101040-00289","volume":"154","author":"JV Freeman","year":"2011","unstructured":"Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Int Med. 2011;154:1\u201311.","journal-title":"Ann Int Med."},{"issue":"d6333","key":"229_CR16","first-page":"1","volume":"343","author":"J Pink","year":"2011","unstructured":"Pink J, Lane S, Pirmohamed M, Hughes DA. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ. 2011;343(d6333):1\u201314.","journal-title":"BMJ"},{"issue":"6","key":"229_CR17","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/jama.293.6.699","volume":"293","author":"CL O\u2019Brien","year":"2005","unstructured":"O\u2019Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA. 2005;293(6):699\u2013706.","journal-title":"JAMA"},{"issue":"2","key":"229_CR18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1161\/01.STR.0000153002.56324.8c","volume":"36","author":"PSJ Miller","year":"2005","unstructured":"Miller PSJ, Andersson FL, Kalra L. Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated? Stroke. 2005;36(2):360\u20136.","journal-title":"Stroke"},{"issue":"6","key":"229_CR19","doi-asserted-by":"crossref","first-page":"e000479","DOI":"10.1161\/JAHA.113.000479","volume":"2","author":"M Sussman","year":"2013","unstructured":"Sussman M, Menzin J, Lin I, et al. Impact of atrial fibrillation on stroke-related healthcare costs. J Am Heart Assoc. 2013;2(6):e000479.","journal-title":"J Am Heart Assoc."},{"issue":"6 Suppl","key":"229_CR20","first-page":"III63","volume":"40","author":"R Etzioni","year":"2002","unstructured":"Etzioni R, Riley GF, Ramsey SD, Brown M. Measuring costs: administrative claims data, clinical trials, and beyond. Med Care. 2002;40(6 Suppl):III63\u201372.","journal-title":"Med Care."},{"issue":"5","key":"229_CR21","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/00005650-199105000-00006","volume":"29","author":"JP Weiner","year":"1991","unstructured":"Weiner JP, Starfield BH, Steinwachs DM, Mumford LM. Development and application of a population-oriented measure of ambulatory care case-mix. Med Care. 1991;29(5):452\u201372.","journal-title":"Med Care"},{"issue":"1","key":"229_CR22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00005650-200101000-00010","volume":"39","author":"RJ Reid","year":"2001","unstructured":"Reid RJ, MacWilliam L, Verhulst L, Roos N, Atkinson M. Performance of the ACG case-mix system in two Canadian provinces. Med Care. 2001;39(1):86\u201399.","journal-title":"Med Care"},{"key":"229_CR23","unstructured":"Wodchis W, Bushmeneva K, Nikitovic M, McKillop I. Guidelines on person-level costing using administrative databases in Ontario. Working Paper Series, vol. 1. Toronto: Health System Performance Research Network; 2013 May. http:\/\/www.hsprn.ca\/uploads\/files\/Guidelines_on_PersonLevel_Costing_May_2013.pdf . Accessed 12 Feb 2016."},{"key":"229_CR24","unstructured":"Government of Canada, Statistics Canada. Consumer Price Index, health and personal care, by province (Canada); 2015. http:\/\/www.statcan.gc.ca\/tables-tableaux\/sum-som\/l01\/cst01\/econ161a-eng.htm . Accessed 28 Jan 2016."},{"key":"229_CR25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3111\/200508147167","volume":"8","author":"R Goeree","year":"2005","unstructured":"Goeree R, Blackhouse G, Petrovic R, Salama S. Cost of stroke in Canada: a 1-year prospective study. J Med Econ. 2005;8:147\u201367.","journal-title":"J Med Econ."},{"key":"229_CR26","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1017\/S0317167100015638","volume":"39","author":"N Mittmann","year":"2012","unstructured":"Mittmann N, Seung SJ, Hill MD, et al. Impact of disability status on ischemic stroke costs in Canada in the first year. Can J Neurol Sci. 2012;39:793\u2013800.","journal-title":"Can J Neurol Sci"},{"issue":"6","key":"229_CR27","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1017\/S0317167100015638","volume":"39","author":"N Mittmann","year":"2012","unstructured":"Mittmann N, Seung SJ, Hill MD, et al. Impact of disability status on ischemic stroke costs in Canada in the first year. Can J Neurol Sci. 2012;39(6):793\u2013800.","journal-title":"Can J Neurol Sci"},{"key":"229_CR28","unstructured":"Ontario Ministry of Health and Long-Term Care. Ontario drug benefits eFormulary. Updated 4 January 2011. https:\/\/www.healthinfo.moh.gov.on.ca\/formulary\/index.jsp . Accessed 10 Dec 2014."},{"issue":"10","key":"229_CR29","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1111\/j.1538-7836.2010.03989.x","volume":"8","author":"S Schulman","year":"2010","unstructured":"Schulman S, Anderson DR, Bungard TJ, Jaeger T, Kahn SR, Wells P, et al. Direct and indirect costs of management of long-term warfarin therapy in Canada. J Thromb Haemost. 2010;8(10):2192\u2013200.","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"229_CR30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/pds.2312","volume":"21","author":"SE Andrade","year":"2012","unstructured":"Andrade SE, Harrold LR, Tjia J, Cutrona SL, Saczynski JS, Dodd KS, et al. A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):100\u201328.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"229_CR31","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2036.2010.04495.x","volume":"33","author":"LA Button","year":"2011","unstructured":"Button LA, Roberts SE, Evans PA, Goldacre MJ, Akbari A, Dsilva R, et al. Hospitalized incidence and case fatality for upper gastrointestinal bleeding from 1999 to 2007: a record linkage study. Aliment Pharmacol Ther. 2011;33(1):64\u201376.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"229_CR32","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1475-6773.2012.01440.x","volume":"48","author":"A Metcalfe","year":"2013","unstructured":"Metcalfe A, Neudam A, Forde S, Liu M, Drosler S, Quan H, et al. Case definitions for acute myocardial infarction in administrative databases and their impact on in-hospital mortality rates. Health Serv Res. 2013;48(1):290\u2013318.","journal-title":"Health Serv Res"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-016-0229-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-016-0229-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-016-0229-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T23:13:08Z","timestamp":1567638788000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-016-0229-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,29]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["229"],"URL":"https:\/\/doi.org\/10.1007\/s40258-016-0229-2","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,29]]}}}